مورد إلكتروني
Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 Randomized Clinical Trial
| العنوان: | Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 Randomized Clinical Trial |
|---|---|
| المصدر: | Rubino , D , Abrahamsson , N , Davies , M , Hesse , D , Greenway , F L , Jensen , C , Lingvay , I , Mosenzon , O , Rosenstock , J , Rubio , M A , Rudofsky , G , Tadayon , S , Wadden , T A , Dicker , D , Sjödin , A M & STEP 4 Investigators 2021 , ' Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 Randomized Clinical Trial ' , JAMA , vol. 325 , no. 14 , pp. 1414-1425 . |
| بيانات النشر: | 2021 |
| تفاصيل مُضافة: | Rubino, Domenica Abrahamsson, Niclas Davies, Melanie Hesse, Dan Greenway, Frank L Jensen, Camilla Lingvay, Ildiko Mosenzon, Ofri Rosenstock, Julio Rubio, Miguel A Rudofsky, Gottfried Tadayon, Sayeh Wadden, Thomas A Dicker, Dror Sjödin, Anders Mikael |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | Importance: The effect of continuing vs withdrawing treatment with semaglutide, a glucagon-like peptide 1 receptor agonist, on weight loss maintenance in people with overweight or obesity is unknown.Objective: To compare continued once-weekly treatment with subcutaneous semaglutide, 2.4 mg, with switch to placebo for weight maintenance (both with lifestyle intervention) in adults with overweight or obesity after a 20-week run-in with subcutaneous semaglutide titrated to 2.4 mg weekly.Design, setting, and participants: Randomized, double-blind, 68-week phase 3a withdrawal study conducted at 73 sites in 10 countries from June 2018 to March 2020 in adults with body mass index of at least 30 (or ≥27 with ≥1 weight-related comorbidity) and without diabetes.Interventions: A total of 902 participants received once-weekly subcutaneous semaglutide during run-in. After 20 weeks (16 weeks of dose escalation; 4 weeks of maintenance dose), 803 participants (89.0%) who reached the 2.4-mg/wk semaglutide maintenance dose were randomized (2:1) to 48 weeks of continued subcutaneous semaglutide (n = 535) or switched to placebo (n = 268), plus lifestyle intervention in both groups.Main outcomes and measures: The primary end point was percent change in body weight from week 20 to week 68; confirmatory secondary end points were changes in waist circumference, systolic blood pressure, and physical functioning (assessed using the Short Form 36 Version 2 Health Survey, Acute Version [SF-36]).Results: Among 803 study participants who completed the 20-week run-in period (with a mean weight loss of 10.6%) and were randomized (mean age, 46 [SD, 12] years; 634 [79%] women; mean body weight, 107.2 kg [SD, 22.7 kg]), 787 participants (98.0%) completed the trial and 741 (92.3%) completed treatment. With continued semaglutide, mean body weight change from week 20 to week 68 was -7.9% vs +6.9% with the switch to placebo ( |
| مصطلحات الفهرس: | Adult, Anti-Obesity Agents/pharmacology, Blood Pressure/drug effects, Double-Blind Method, Female, Glucagon-Like Peptide 1/agonists, Glucagon-Like Peptides/adverse effects, Humans, Injections, Subcutaneous, Male, Middle Aged, Obesity/drug therapy, Overweight/drug therapy, Waist Circumference/drug effects, Weight Loss/drug effects, article |
| URL: | |
| الإتاحة: | Open access content. Open access content info:eu-repo/semantics/openAccess |
| ملاحظة: | application/pdf English |
| أرقام أخرى: | DAV oai:pure.atira.dk:publications/4c7bb83b-26fa-40e2-95fb-421e5be0da6d 1322772433 |
| المصدر المساهم: | UNIV OF COPENHAGEN From OAIster®, provided by the OCLC Cooperative. |
| رقم الأكسشن: | edsoai.on1322772433 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |